Gilead Sciences, Inc.
NEWS
It was a busy week for clinical trial updates. Here’s a look.
Today, Gilead announced that it was acquiring a 49.9% equity interest in Pionyr Immunotherapeutics for $275 million and exclusive option to buy the rest of the company.
In an open letter from the company’s chairman and chief executive officer, Daniel O’Day reported that the U.S. Food and Drug Administration (FDA) had given the company approval to begin clinical trials of an inhaled version of the drug.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.
Shares of Gilead Sciences jumped in pre-market trading this weekend following reports that the company has been approached by U.K. pharma giant AstraZeneca regarding a potential merger.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
JOBS
IN THE PRESS